drugset / Trial / NCT00214435
Once Daily 3TC, Efavirenz and ddI for HIV Infection
Phase 4
Unknown
120 enrolled
407 Doctors
Bristol-Myers Squibb · collabMerck Sharp & Dohme LLC · collab
RandomizedCrossoverOpen-labelTreatment
Summary
Poor compliance is thought to be a major cause of treatment failure. The TEddI study is a randomised, multi-centre, open-label study in well-controlled treatment-experienced HIV-infected patients to assess compliance with a once-daily regimen of antiretroviral therapy versus continuation of current anti-retroviral regimen delivered at least twice daily.
Timeline
- Start
- 2004-05
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Didanosine | Small molecule | — | — |
| Subject | Efavirenz | Other / unclassified | — | — |
| Subject | Lamivudine | Other / unclassified | — | — |
| Subject | TDF | Unknown | — | — |
| Subject | once daily minimum 3-drug regimen of anti-retroviral medications | Unknown | — | — |